Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Pulmonary Infections
Have you incorporated the use of MycoTOX profiles into your clinical practice and, if so, in what capacity?
Are results showing Gliotoxin and Chaetoglobosin A clinically relevant?
Related Questions
Do you integrate inhaled colistimethate sodium into existing treatment regimens for patients with bronchiectasis and PSAR infection?
How do you consider sending fungal studies in a patient with pneumonia?
How do you manage resistant infections that persist after stopping antibiotic therapy in patients with non-CF bronchiectasis?
What is the recommended fungal workup in an immunocompromised patient after 5 days of persistent fever?
In light of recent measles outbreaks in the US, would you recommend an MMR booster for an immunocompetent patients born before 1957?
How do you approach a positive IGRA in a patient with idiopathic NSIP needing a prolonged course of corticosteroid therapy and a prior history MAC in a single sputum culture?
Would you start treatment for MAC in a patient with nodular bronchiectatic disease who has demonstrated radiographic progression but remains asymptomatic and smear-negative?
Do you routinely integrate the use of a multiplex PCR panel in the evaluation and diagnosis of patients suspected of having VAP?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
What is your preferred agent for fungal prophylaxis in a patient post lung transplant with abnormal LFTs?